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Abstract
Human ABCG2, a member of the ATP-binding cassette transporter superfamily, plays a key role in multidrug resistance and
protecting cancer stem cells. ABCG2-knockout had no apparent adverse effect on the development, biochemistry, and life
of mice. Thus, ABCG2 is an interesting and promising target for development of chemo-sensitizing agents for better
treatment of drug resistant cancers and for eliminating cancer stem cells. Previously, we reported a novel two mode-acting
ABCG2 inhibitor, PZ-39, that induces ABCG2 degradation in addition to inhibiting its activity. In this manuscript, we report
our recent progresses in identifying two different groups of ABCG2 inhibitors with one inhibiting only ABCG2 function
(static) and the other induces ABCG2 degradation in lysosome in addition to inhibiting its function (dynamic). Thus, the
inhibitor-induced ABCG2 degradation may be more common than we previously anticipated and further investigation of
the dynamic inhibitors that induce ABCG2 degradation may provide a more effective way of sensitizing ABCG2-mediated
MDR in cancer chemotherapy.
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Introduction
ABCG2 is a member of the ATP-binding cassette (ABC)
transporter superfamily and over-expression of ABCG2 has been
shown to cause multidrug resistance (MDR) in model cancer cell
lines and to correlate with poor prognosis in both adult and
childhood leukemia and breast cancer patients (for reviews see
[1,2,3]). Unlike most other members of the ABC transporter
superfamily such as P-glycoprotein (MDR1/ABCB1), ABCG2 is
considered as a half transporter consisting of one nucleotide-
binding domain (NBD) at amino terminus and one membrane-
spanning domain (MSD) at carboxyl terminus. It has, thus, been
thought to exist and function as a homo-dimer. However, recent
evidence showed that ABCG2 may exist and function as a higher
order of oligomer consisting of 8–12 identical subunits [4,5] and
the oligomerization sites are likely located in the MSD [6].
In the process of aiming to sensitize MDR mediated by
ABCG2, a number of ABCG2 inhibitors have been recently
discovered [7,8,9,10,11,12] in addition to the previously identified
ones such as Fumitremorgin C (FTC) (for a review see [2]). One of
these ABCG2 inhibitors, PZ-39, was very effective and distinctive
from others such as FTC with the ability to cause lysosome-
dependent degradation of ABCG2 protein [7].
To further determine if inhibitor-induced ABCG2 degradation
is unique to PZ-39, we tested other ABCG2 inhibitors generated
during our initial screening which led to identification of PZ-39.
We found two types of ABCG2 inhibitors with one inhibiting
ABCG2 activity only (static) and the other inhibiting ABCG2
activity as well as inducing ABCG2 degradation via lysosome
(dynamic). These findings suggest that inhibitor-induced ABCG2
degradation in lysosome may be more common than it has
previously been anticipated and further investigating the dynamic
inhibitors that induce ABCG2 degradation in lysosome may
provide a more effective way of sensitizing ABCG2-mediated
MDR in cancer chemotherapy.
Results
Two types of ABCG2 inhibitors
Previously, we reported that the rational screening of represen-
tatives of different types of compound library from Specs (www.
specs.net) led to identification of a two-mode acting ABCG2
inhibitor PZ-39 [7]. During the initial screening, several other
ABCG2 inhibitors, which are structurally different from PZ-39
and its derivatives (Fig. 1), were also identified and their activity
to inhibit ABCG2-mediated drug efflux has been confirmed using
HEK293 cells with over-expression of ectopic ABCG2 (HEK293/
ABCG2) (Fig. 2A). To determine if these inhibitors also posses the
two-mode acting property, we first tested the effect of these
inhibitors on ABCG2 expression using Western blot analysis. As
shown in Fig. 2B, three of the four new inhibitors (PZ-8, 34, and
38) along with PZ-39 inhibit ABCG2 expression while PZ-16
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only ABCG2 activity [7], we conclude that there are likely two
types of ABCG2 inhibitors with one inhibiting only ABCG2
activity while the other inhibiting both the activity and expression
of ABCG2.
Suppression of ABCG2 expression by the known and
existing ABCG2 inhibitors
The above results suggest that the inhibitor-induced suppression
of ABCG2 expression may be more common than anticipated. To
further test this possibility, we investigated the effect of two other
Figure 1. Structures of PZ-8, 16, 34 and 38 in comparison with PZ-39. The chemical structures are shown for PZ-8, (12E)-N’-((5-(3,4-dihydro-4-
oxo-3-phenylquinazolin-2-ylthio)furan-2-yl)methylene)-2-(4-ethylphenoxy)acetohydrazide; PZ-16, 2-(4-(4-nitrophenoxy)phenyl)-2-oxoethyl2-(2-(4-
chloro benzamido)acetamido)acetate; PZ-34, (E)-2-(4-ethoxyphenyl)-N’-(1-(4-(furan-2-carboxamido) phenyl)ethylidene)quinoline-4-carbohydrazide;
PZ-38, (N-(2,5-dimethoxyphenyl)-2-({4-[4-(dimethylamino)benzylidene]-5-oxo-1-phenyl-4,5-dihydro-1H-imidazol-2-yl}sulfanyl)acetamide); and PZ-39
(N-(4-chlorophenyl)-2-[(6-{[4,6-di(4- morpholinyl)-1,3,5- triazin-2-yl] amino}-1,3-benzothiazol-2-yl)sulfanyl]acetamide).
doi:10.1371/journal.pone.0015276.g001
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on ABCG2 expression using Western blot analysis. As shown in
Fig. 3A, both NSC-168201 and NSC-120668 effectively suppress
ABCG2 expression. However, the control ABCG2 inhibitor FTC
does not although all three inhibitors effectively enhance mitoxan-
trone accumulation in HEK293/ABCG2 cell lines (Fig. 3B). Thus,
we conclude that the inhibitor-induced suppression of ABCG2
expression may be more common than it has been anticipated and
there are possibly two groups of ABCG2 inhibitors.
Specific effect of PZ-34 and PZ-38 on ABCG2-mediated
mitoxantrone efflux
To further investigate if these new inhibitors suppress ABCG2
expression by inducing ABCG2 degradation in lysosome, we chose
Figure 2. Effect of PZ compounds on mitoxantrone accumulation and ABCG2 expression. A, mitoxantrone accumulation. HEK293/ABCG2
cells were incubated with mitoxantrone for 30 min in the presence of DMSO (thin line) or 10 mM PZ compounds (thick line) followed by FACS analysis
of mitoxantrone level. B, ABCG2 expression. HEK293/ABCG2 cells were incubated with 3.3 mM PZ compounds or DMSO control for various times
followed by collection of cells and Western blot analysis of ABCG2 probed with monoclonal antibody BXP-21.
doi:10.1371/journal.pone.0015276.g002
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analysis of their effects on drug accumulation. As shown in Fig. 4A,
both PZ-34 and PZ-38 at ,4 mM increase mitoxantrone
accumulation to a similar degree as the well-established ABCG2
inhibitor FTC in HEK293/ABCG2 cells. These compounds,
however, have no significant effect on mitoxantrone accumulation
in the control cells-transfected with vector (HEK293/Vec),
indicating that the effect of PZ-34 and PZ-38 on mitoxantrone
accumulation is likely via inhibiting ABCG2. We then tested the
dose response of PZ-34 and PZ-38 in inhibiting ABCG2-mediated
mitoxantrone efflux in HEK293/ABCG2 cells using flow
cytometry. As shown in Fig. 4B, the intracellular mitoxantrone
level is much less in HEK293/ABCG2 cells compared with
HEK293/Vec cells due to ABCG2-mediated efflux. Addition of
PZ-34 and PZ-38 increases the intracellular accumulation of
mitoxantrone in a dose-dependent manner similar as FTC.
To determine the specificity of PZ-34 and PZ-38, we tested their
effect on drug efflux mediated by two other ABC transporters that
are known to cause MDR, ABCB1 and ABCC1, using MCF7
cells-transfected with ABCB1 (BC19) [13] and HEK293 cells-
transfected with ABCC1 (HEK293/ABCC1) [14,15]. However,
we found no effect of these compounds on the activity of ABCB1
and ABCC1 in decreasing Adriamycin accumulation (Fig. 4C).
Both PZ-34 and PZ-38 also do not affect the expression of ABCB1
and ABCC1 (Fig. 4D). Thus, PZ-34 and PZ-38 may be specific to
ABCG2 and do not affect drug efflux mediated by two other major
ABC transporters.
Effect of PZ-34 and PZ-38 on ABCG2-mediated multidrug
resistance
To determine if both PZ-34 and PZ-38 have the ability to
sensitize ABCG2-mediated drug resistance, we performed analyses
of the effects of these compounds on survival of HEK293/ABCG2
cells in the absence or presence of mitoxantrone. As shown in
Fig. 5A, both PZ-34 and PZ-38 alone have no effect on the
survival of HEK293/ABCG2 cells at concentrations less than
10 mg/ml. Their IC50 were estimated to be ,12.9 and .20 mM,
respectively (Table 1). Thus, both PZ-34 and PZ-38 have little
cytotoxicity to HEK293/ABCG2 cells at concentrations less than
10 mM, suggesting that they may not act on other essential
molecules with high affinity for cell survival.
We next determined the effect of PZ-34 and PZ-38 on
sensitizing cellular response to 0.1 mM mitoxantrone which alone
produces less than 10% inhibition of growth of HEK293/ABCG2
cells. As shown in Fig. 5A, both PZ-34 and PZ-38 at a low
concentration range sensitize these cells to mitoxantrone. At about
1.2 mM, both PZ-34 and PZ-38 assist 0.1 mM mitoxantrone to
completely inhibit cell growth. The IC50 of PZ-34 and PZ-38 in
sensitizing mitoxantrone resistance were calculated to be 71 and
45 nM, respectively (Table 1). We also tested PZ-8 and PZ-16 and
found that the IC50 of these compounds alone is ,20 mM and
their IC50 in sensitizing mitoxantrone resistance of MCF7/
AdVp3000 cells are ,80 and ,70 nM, respectively. The IC50
of FTC in sensitizing mitoxantrone resistance, on the other hand,
is much higher at 326 nM (Table 1).
Next, we examined the dose response of PZ-34 and PZ-38 in
sensitizing ABCG2-mediated mitoxantrone resistance using
HEK293/ABCG2 cells. As shown in Fig. 5B, the IC50 of
mitoxantrone decreases dramatically in the presence of PZ-34
and PZ-38. At 50 nM, PZ-34 and PZ-38 significantly reduce the
IC50 of mitoxantrone with a sensitization index of 1.6 and 2.2,
respectively (Table 2). At 500 nM, the sensitization index of PZ-34
and PZ-38 are 8.7 and 14.3, respectively (Table 2). On the other
hand, the sensitization index of FTC at 500 nM is only 3.9
(Table 2). These results show that PZ-34 and PZ-38 are very
potent novel ABCG2 inhibitors.
To further investigate if PZ-34 and PZ-38 can reverse ABCG2-
mediated MDR in a drug resistant cancer cell line, we used the
drug-selected breast cancer cell line MCF7/AdVp3000 which
Figure 3. Effect of NSC compounds on ABCG2 expression and mitoxantrone efflux. A, ABCG2 expression. HEK293/ABCG2 cells were
treated with 10 mM each of the known ABCG2 inhibitors NSC-168201, NSC-120668, or FTC for various times followed by Western blot analysis of
ABCG2 expression probed with monoclonal antibody BXP-21. B, mitoxantrone accumulation. HEK293/ABCG2 cells were incubated with mitoxantrone
for 30 min in the presence of DMSO (thin line) or 10 mM NSC-168201, NSC-120668, or FTC (thick line) followed by FACS analysis of intracellular
mitoxantrone level.
doi:10.1371/journal.pone.0015276.g003
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PLoS ONE | www.plosone.org 4 December 2010 | Volume 5 | Issue 12 | e15276Figure 4. PZ-34 and PZ-38 inhibition of ABCG2-mediated mitoxantrone efflux. A, mitoxantrone accumulation. HEK293/Vec or HEK293/
ABCG2 cells were incubated with mitoxantrone for 30 minute in the presence of DMSO control, or 3 mM of PZ-34, PZ-38 or FTC control. The data are
means 6 SD from three independent experiments. B, dose response of PZ-34, PZ-38, and FTC control in restoring mitoxantrone accumulation in
HEK293/ABCG2 cells. The thick line shows the level of mitoxantrone accumulation in HEK293/Vec cells, serving as a maximum accumulation control.
C, effect on ABCB1 and ABCC1-mediated Adriamycin efflux. HEK293 cells with ABCC1 over-expression (HEK293/ABCC1) and BC19 cells with ABCB1
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substrate of ABCG2, Adriamycin. As shown in Fig. 5C, both PZ-
34 and PZ-38 at 500 nM drastically reduce the resistance of
MCF7/AdVp3000 to both Adriamycin and mitoxantrone.
PZ-34 and PZ-38 do not affect ABCG2 oligomerization
Previously, it has been shown that ABCG2 may exist and
function as a homo-oligomer [4,6]. To examine if PZ-34 and PZ-
38 possibly inhibit ABCG2 oligomerization, co-immunoprecipita-
tion of two differentially tagged ABCG2 was performed as
previously described [4] following a 6-hr treatment with PZ-34
and PZ-38 at 3.3 mM. However, no effect of PZ-34 and PZ-38 on
ABCG2 co-immunoprecipitation was found (see supplemental Fig.
S1), suggesting that PZ-34 and PZ-38, similar to PZ-39 [7], may
not affect ABCG2 oligomerization. However, due to the limitation
of co-immunoprecipitation, these inhibitors may affect dimeriza-
tion which can not be revealed by co-immunoprecipitation due to
the existence of at least 3 different interaction sites of the
oligomeric ABCG2 [4,6].
Effect of PZ-34 and PZ-38 on the half-life of ABCG2
As discussed above, both PZ-34 and PZ-38 suppressed ABCG2
expression (Fig. 2). To rule out the possibility that this suppres-
sion is due to inhibition of gene expression, we performed real
time RT-PCR analysis. As shown in Fig. S2, the steady state
levels of ABCG2 mRNA are the same between control and
compound treatment groups and, thus, eliminating the possibility
that these compounds affect the transcription or stability of
ABCG2 mRNAs.
To determine if the suppressed expression of ABCG2 is due to
inhibitor-induced degradation as we previously observed with PZ-
39 [7], we examined the effect of PZ-34 and PZ-38 on the half-life
of ABCG2 in HEK293/ABCG2 cells by pre-treating cells with
cycloheximide, which inhibits elongation during protein synthesis,
followed by treatment with PZ-34 and PZ-38 for various times. As
shown in Fig. 6A, the loss of ABCG2 in cells treated with a
combination of cycloheximide and PZ-34 or PZ-38 is much faster
than that of the control treatment with DMSO vehicle or FTC
control. The half-life of ABCG2 in the presence of PZ-34 and PZ-
38 is estimated to be ,8 hrs whereas it is stable with an estimated
half-life more than 60 hrs in the control treatment with FTC or
DMSO (Fig. 6B). Thus, PZ-34 and PZ-38 likely accelerates the
degradation of ABCG2 protein similarly as PZ-39 [7].
PZ-34 and PZ-38 induce ABCG2 degradation in lysosome
It has been reported previously that wild-type and correctly-
folded ABCG2 proteins are degraded in lysosome whereas the
mutant and misfolded proteins are involved in ubiquitin-mediated
degradation in proteasome [16]. In addition, we found previously
that PZ-39 causes ABCG2 degradation via lysosome-mediated
degradation [7]. To determine if PZ-34 and PZ-38 cause ABCG2
degradation via lysosome or proteasome, we used Bafilomycin A1,
an inhibitor of protein degradation in lysosome, and MG-132, a
proteasome inhibitor as previously described [7]. As shown in
over-expression were incubated with Adriamycin in the absence (gray area) or presence (dotted line) of 3.8 mM PZ-34 or PZ-38 followed by FACS
analysis. The thick line indicates the maximum level of accumulation in cells transfected with vector control. D, effect on ABCB1 and ABCC1
expression. HEK293/ABCC1 and BC19 cells with ABCB1 over-expression were treated with 10 mM PZ-34 or PZ-38 for 3 days followed by Western blot
analysis of ABCB1 using monoclonal antibody C219 and ABCC1 using monoclonal antibody MRPr1. GAPDH was used as a loading control.
doi:10.1371/journal.pone.0015276.g004
Figure 5. Effect of PZ-34 and PZ-38 on sensitizing drug resistance. A, potency of PZ-34 and PZ-38 in reversing mitoxantrone resistance.
HEK293/ABCG2 cells were treated without or with 0.1 mM (IC10) mitoxantrone in the absence or presence of different concentrations of PZ-34 or PZ-
38 followed by SRB assay. B, sensitization index of PZ-34 and PZ-38 in HEK293/ABCG2 cells. HEK293/ABCG2 cells were treated with various
concentrations of mitoxantrone in the absence or presence of different concentrations of PZ-34 or PZ-38 followed by SRB assay. C and D, sensitization
index of PZ-34 and PZ-38 in drug-selected MCF7/AdVp3000 cells. MCF7/AdVp3000 cells were treated with various concentrations of mitoxantrone (C),
or Adriamycin (D) in the presence of DMSO (vehicle) or 500 nM of PZ-34 and PZ-38 followed by MTT assay. Sensitization index was calculated using
IC50 of the anticancer drugs in the absence or presence of PZ-34, PZ-38, or FTC. The data shown are mean 6 SD of three independent experiments.
doi:10.1371/journal.pone.0015276.g005
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and PZ-38-induced ABCG2 degradation whereas pre-treatment
with MG-132 does not. Thus, likely PZ-34 and PZ-38 also induce
ABCG2 degradation in lysosome, same as PZ-39 [7].
PZ-34 and PZ-38 bind to ABCG2
It has been reported previously that the monoclonal antibody
5D3 binds to ABCG2 on cell surface more readily upon binding of
inhibitors to ABCG2 possibly due to inhibitor-induced conforma-
tional changes of ABCG2 [7,12,17]. To determine if PZ-34 and
PZ-38 potentially bind to ABCG2, we performed staining analyses
of ABCG2 using 5D3 in the presence or absence of PZ-34 and PZ-
38. As shown in Fig. 7B, both PZ-34 and PZ-38 cause an increase
in 5D3 staining in both MCF7/AdVp3000 and HEK293/ABCG2
cells, indicating that both PZ-34 and PZ-38 may bind to ABCG2
and the binding leads to the conformational change of ABCG2.
Discussion
In the present study, we show that there are possibly two groups
of ABCG2 inhibitors and the inhibitor-induced ABCG2 degrada-
tion in lysosome may be more common than previously anticipated.
We also show that PZ-34 and PZ-38 are potent ABCG2 inhibitors.
Although PZ-34 and PZ-38 are structurally different from the
previously identified ABCG2 inhibitor, PZ-39, they appear to have
similar mechanism of action by inhibiting ABCG2 function and by
accelerating ABCG2 degradation in lysosome.
Among many ABCG2 inhibitors previously identified, few are
known to be specific to ABCG2 and none has been investigated to
show if they could accelerate ABCG2 degradation in lysosome. In
this and our previous studies [7], we found that FTC did not affect
ABCG2 expression whereas both NSC-168201 and NSC-120668
did. In the four new ABCG2 inhibitors (PZ-8, 16, 34, and 38)
tested in this study, three suppressed ABCG2 expression while the
other did not. Taken together, we believe that there are two
groups of ABCG2 inhibitors with one inhibiting only ABCG2
activity and the other also suppressing ABCG2 degradation in
addition to inhibiting ABCG2 function. We name these inhibitors
as static and dynamic inhibitors, respectively.
It is currently unknown what fundamental differences between
these two groups of inhibitors cause the difference in their
mechanism of action. It is, however, tempting to speculate that
they bind to two different sites on ABCG2.Binding to either site will
causeconformationalchangesofABCG2whichlead toinhibitionof
ABCG2 activity. However, binding to one of the sites will also
facilitate ABCG2 endocytosis and degradation in lysosome. The
change of ABCG2 conformation by PZ-34 and PZ-38 detected
using the monoclonal antibody 5D3 suggests that PZ-34 and PZ-38
directly bind to ABCG2 although their binding sites are currently
unknown. Since FTC also causes conformational change but does
not accelerate ABCG2 degradation, PZ-34 and PZ-38 likely do not
bind to the similar site as FTC. Previously, it has been shown that
agonist binding accelerated endocytosis and degradation of b2-
adrenergic receptor in lysosome [18], supporting the above
hypothesis. Although unlikely, it is also possible that the dynamic
ABCG2 inhibitors may have off-target effect that activates the
upstream pathways involved in ABCG2 degradation. Regardless,
these possibilities need to be tested in future in-depth studies.
Previously, it has been shown that ABCG2 degradation occurs
mainly via two different mechanisms. While correctly folded wild
type ABCG2 are mainly degraded via lysosome [16], the mutant
proteins are degraded by proteasome via a quality control
mechanism [16,19,20]. It appears that the quality control
mechanism occurs at the ER right after the synthesis of ABCG2
and normal degradation of the wild type proteins may occur
through endocytosis of ABCG2 from plasma membranes.
Currently, it is not yet known if the dynamic inhibitor-induced
degradation of ABCG2 occurs by trafficking to lysosome from
plasma membranes via endocytosis and/or from ER membranes
immediately following their synthesis.
Although it is currently unknown if PZ-34 and PZ-38 are
specific to ABCG2, our results show that they do not affect
ABCB1 and ABCC1 function and expression. Thus, PZ-34 and
PZ-38 are more specific to ABCG2 than some of the previously
identified ABCG2 inhibitors such as the known ABCG2 inhibitor
GF120918 which appears to inhibit ABCB1 and/or ABCC1
equally well [2,21]. We also found that both PZ-34 and PZ-38 are
not cytotoxic with a concentration up to 10 mg/ml, suggesting that
these ABCG2 inhibitors probably do not bind to and inhibit other
cellular proteins with high affinity that are essential for cellular
survival. However, more studies are needed to investigate the
specificity of PZ-34 and PZ-38 and to determine if they bind to
and inhibit other members of the human ABC transporter family.
The fact that PZ-34 and PZ-38 have no cytotoxicity to HEK293
cells at concentrations less than 10 mM and can effectively reverse
MDR suggests that the window of therapeutic index of these
compounds are large. An ideal chemo-sensitizer is that it should
not be toxic itself. Clearly, PZ-34 and PZ-38 satisfy this
requirement in the in-vitro studies. However, it is not known if
these compounds are toxic and effective in reversing MDR in vivo,
which need to be evaluated in future studies using animal models.
Materials and Methods
Materials
Monoclonal antibody BXP-21 against ABCG2, anti-Myc and
anti-HA antibodies were from ID Labs, Cell Signaling, and
Table 1. Potency index of PZ-34 and PZ-38 for sensitization
of mitoxantrone resistance in HEK293/ABCG2 cells.
IC50 (mM) of inhibitor
Inhibitor alone Inhibitor + MX
a Potency Index
b
PZ-34 12.9460.15 0.07160.01 182
PZ-38 .20 0.04560.031 .444
FTC 24.861.4 0.32660.086 76
a.MX=mitoxantrone at 100 nM that produces #10% inhibition of growth (IC10).
b.Potency Index=ratio of inhibitor IC50 in the absence and presence of
mitoxantrone at low concentration (,IC10).
doi:10.1371/journal.pone.0015276.t001
Table 2. Sensitization index of PZ-34 and PZ-38 on
mitoxantrone resistance in HEK293/ABCG2 cells.
IC50 (nM) of Mitoxantrone and SI
a
50 nM SI 200 nM SI 500 nM SI
PZ-34 346.6658.8 1.6 149.7613.4 3.7 63.7610.7 8.7
PZ-38 250.0638.2 2.2 91.6624.2 6.0 38.7613.3 14.3
FTC 467.8642.6 1.2 254.767.9 2.2 143.1639.3 3.9
a.SI=Sensitization Index, determined by dividing median IC50 of mitoxantrone
(551 nM) in the presence of vehicle (0.1% DMSO) by IC50 of mitoxantrone in
the presence of inhibitor.
doi:10.1371/journal.pone.0015276.t002
ABCG2 Degradation-Inducing Inhibitors
PLoS ONE | www.plosone.org 7 December 2010 | Volume 5 | Issue 12 | e15276Roche, respectively. Monoclonal antibody C219 and MRPr1 were
purchased from Kamiya Biomedical Company. Biotin-conjugated
5D3 antibody and Phycoerythrin-Streptavidin conjugates were
from eBiosciences. All electrophoresis reagents, protein concen-
tration assay kit, and polyvinylidene difluoride membranes were
purchased from Bio-Rad. FTC, Adriamycin, mitoxantrone,
camptothecin, dithiothreitol, Sulforhodamine B (SRB), and Triton
X-100 were from Sigma. Compounds PZ-8, PZ-16, PZ-34, PZ-38,
and PZ-39 were purchased from SPECS. NSC-168201 and NSC-
120668 were gifts from National Cancer Institute. Protein-G
PLUS-Agarose and SYBR Green PCR Master Mix were from
Santa Cruz Biotechnology and Applied Biosystems, respectively.
LipofectAMINE Plus and G418 were from Invitrogen. Cell
culture medium IMEM and DMEM were from BioSource
International and Media Tech, respectively. All other chemicals
were of molecular biology grades from Sigma or Fisher Scientific.
Cell culture, treatments and lysate preparations
Human breast cancer cell line MCF7 and its derivative lines
BC19 (a gift from Julie Horton at National Institute of Environ-
mental Health Sciences) and MCF7/AdVp3000 (a gift from Susan
Bates at National Cancer Institute), HEK293/ABCC1 [14],
HEK293/vector [14], HEK293/ABCG2 [4] were cultured as
previously described [4,13,14,22]. For analysis of ABCG2 degra-
dation, HEK293/ABCG2 cells were first treated with 10 nM
Bafilomycin A1 or 2 mM MG132 for 24 hrs followed by treatment
with 3 mM PZ-34 or PZ-38 for various times and collection of cell
lysates. For the determination of ABCG2 half-life, HEK293/
ABCG2 cells were treated with 5 mg/ml cycloheximide, 3 mMP Z -
34 or PZ-38 for various times followed by collection of cells. Lysate
preparation was performed as described previously [22].
Western blot, immunoprecipitation, and FACS analyses
Western blot, immunoprecipitation, and FACS analyses of drug
accumulation were performed exactly as we previously described
[4,6]. To determine the conformational change of ABCG2 following
treatment with ABCG2 inhibitors, HEK293/ABCG2 cells were
incubated with 10 mM PZ-34 or PZ-38 at 37uC for 30 min before
incubating with biotin-conjugated 5D3 antibody (1:100 dilution) for
2 hrs. The cells were then washed 3 times and incubated with
Phycoerythrin-Streptavidin for 30 min followed by washing and
analysis using FACS.
Cytotoxicity assay
Cytotoxicity was determined using SRB and MTT assays as
previously described [6,22,23]. The effect of ABCG2 inhibitors on
drug resistance was determined by exposing cells to a range of
concentrations of anticancer drugs in the absence or presence of
different concentrations of ABCG2 inhibitors. The potency and
sensitization index of ABCG2 inhibitors were calculated as follows:
Potency index~IC50 inhibitor ðÞ =IC50 inhibitorzdrug ðÞ
Sensitization index~ IC50 drug ðÞ =IC50 drugzinhibitor ðÞ
Real time RT-PCR
RNA extraction and real-time RT-PCR were performed as we
described previously [22]. The sequences of ABCG2primers are59-
GGCTTTCTACCTGCACGAAAACCAGTTGAG-39 (forward)
and 59-ATGGCGTTGAGACCAG-39 (reverse). The sequences of
Figure 6. Effect of PZ-34 and PZ-38 on ABCG2 stability. A, Western blot analysis. HEK293/ABCG2 cells were first treated with 5 mg/ml
cycloheximide (CHX) followed by addition of 3 mM of PZ-34, PZ-38, FTC, or DMSO control for various times. The cells were then harvested for Western
blot analysis of ABCG2 probed with monoclonal antibody BXP-21. Actin was used as a loading control. B, half-life of ABCG2. ABCG2 levels on Western
blot as shown in panel A were determined using Scion Image and plotted against time of treatment. Data shown are mean6 S.D of three experiments.
doi:10.1371/journal.pone.0015276.g006
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39 (forward) and 59-CCATCACGCCACAGTTTCC-39 (reverse).
The relative ABCG2 RNA level (2
DCT) treated with inhibitors was
expressed as percentage of the control (in the presence of 0.1%
DMSO) where DCT (threshold cycle) = (CTABCG2-CTGAPDH).
Supporting Information
Figure S1 Effect of PZ-34 and PZ-38 on ABCG2 dimer-
ization/oligomerization. HEK293 cells co-transfected with
Myc- and HA-tagged ABCG2 were exposed to 3.3 mM PZ-34,
PZ-38, or DMSO control for 6 hrs and cell lysates were subjected
to immunoprecipitation with anti-Myc or anti-HA monoclonal
antibody followed by western blot analysis probed using anti-HA
and anti-Myc antibodies.
(JPG)
Figure S2 Effect of PZ-34 and PZ-38 on ABCG2 mRNA
level. HEK293/ABCG2 cells were treated with DMSO vehicle,
PZ-34, or PZ-38 for various times and harvested for RNA
preparation and real-time RT-PCR analysis. Data shown are
mean 6 SD from three independent experiments.
(JPG)
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Figure 7. PZ-34 and PZ-38-binding induced ABCG2 degradation and conformational change. A, ABCG2 degradation in lysosomes.
HEK293/ABCG2 cells were treated with 3 mM of PZ-34 or PZ-38 in the absence or presence of 10 nM Bafilomycin A1 (BMA1) or 2 mM MG-132 for
various times. The cells were then harvested for Western blot analysis of ABCG2 expression probed with monoclonal antibody BXP-21. Actin was used
as a loading control. B, ABCG2 conformational changes. HEK293/ABCG2 and MCF7/AdVp3000 cells were treated with 10 mM of PZ-34, PZ-38, or DMSO
vehicle control followed by staining with monoclonal antibody 5D3 and FACS analysis. Arrowhead indicate the PZ-34 and PZ-38 treated groups.
doi:10.1371/journal.pone.0015276.g007
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